Bullish & Foolish
Full IVF fundamentals All 466 on the Survival Watch

IVFINVO Fertility, Inc.

Is INVO Fertility struggling financially?

Yes, by its own account. INVO Fertility told the SEC on 23 Jun 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Jun 2026

28/100

Fragile

Cries for help

  • Restated accounts

    On June 1, 2026, our Audit Committee, after considering the recommendations of management, concluded that our Previous Financial Statements should no longer be relied upon.

    Form DEF 14A, filed 23 Jun 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$2.7M
Source filing
DEF 14A 23 Jun 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$7.1M

What INVO Fertility told the SEC

…and have been properly applied. M&K’s audit reports for the fiscal years ended December 31, 2023 and December 31, 2024 do, however, contain an expression of substantial doubt regarding the Company’s ability to continue as a going concern. During the Company’s two most recent fiscal years and the subsequent interim period through September 5, 2025, there were no: (i) disagreements, as defined in Item 304(a)(1)(iv) of…

INVO Fertility, Inc., Form DEF 14A, filed 23 Jun 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 526.2% share-count increase The company issued stock. Each share now owns 84.0% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 41% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt